Table 4—

Blood pressure and serum lipid levels at study entry and week 52 and changes over 52 weeks of treatment

PlaceboOrlistatP
n276266
Systolic blood pressure (mmHg)
 Initial134.9 ± 0.9135.1 ± 0.9
 52 weeks134.0 ± 1.0134.0 ± 1.0
 Change−0.9 ± 1.0−1.2 ± 1.00.948
Diastolic blood pressure (mmHg)
 Initial80.9 ± 0.679.5 ± 0.5
 52 weeks78.0 ± 0.577.2 ± 0.6
 Change−1.0 ± 0.5−2.3 ± 0.70.075
Total cholesterol (mmol/l)
 Initial5.43 ± 0.075.49 ± 0.07
 Week 525.46 ± 0.085.20 ± 0.08
 Change0.08 ± 0.07−0.30 ± 0.070.002
 Percent change2.61 ± 1.21−4.66 ± 1.07
LDL cholesterol (mmol/l)
 Initial3.30 ± 0.063.37 ± 0.06
 Week 523.18 ± 0.063.00 ± 0.06
 Change−0.08 ± 0.05−0.38 ± 0.050.001
 Percent change0.83 ± 1.9−9.06 ± 1.5
HDL cholesterol (mmol/l)
 Initial1.07 ± 0.021.07 ± 0.02
 Week 521.12 ± 0.021.09 ± 0.02
 Change0.05 ± 0.010.02 ± 0.010.247
 Percent change6.44 ± 1.293.95 ± 1.30
LDL/HDL ratio
 Initial3.27 ± 0.073.38 ± 0.08
 Week 522.98 ± 0.072.88 ± 0.07
 Change−0.25 ± 0.06−0.50 ± 0.070.013
 Percent change−3.50 ± 1.9−10.11 ± 1.8
Triglycerides (mmol/l)
 Initial2.31 ± 0.082.33 ± 0.1
 Week 522.61 ± 0.172.47 ± 0.18
 Change0.31 ± 0.130.18 ± 0.160.421
 Percent change17.27 ± 3.7010.01 ± 3.41
  • Data are means ± SE. Intent-to-treat population; last observation carried forward.